Virion production is significantly decreased by rapamycin treatment. by Lisa A. Nichols (357612)

FUD transiently decreased IOP in mice injected with Ad5-TGFβ2 viral vector. by Jennifer A. Faralli (4907311)

“…(B) IOPs were monitored for 5 more days (until Day 22) in a subset of mice from A. …”

Filter-extruded niosomes decrease in size upon freezing and thawing. by Rianne Bartelds (1343631)

“…As guidance, all niosomes are indicated with a red arrow in the right picture. In contrast, cryo-EM pictures of liposomes composed of unsaturated lipids plus cholesterol without (D) and with five freeze and thaw cycles (E) appear similar in size but the degree of multilamellarity decreases by the freezing-thawing and subsequent extrusion step.…”

Loss of FOXP1 results in decreased number of bRGCs. by Seon Hye E. Park (16765033)

Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

“…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C⁺ and CD163⁺ macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C⁺, CD163⁺: proinflammatory macrophage cell-surface markers.…”

IMP-1088 decreases infectivity of progeny VACV particles. by Lalita Priyamvada (421536)

Serotype distributions over time for reported "non-PCV" serotypes. by Heloisa Ricci Conesa (18291210)

Subjects:

Oleic acid treatment decreases MDA formation, and induces UCP2 and AMPK in septic mice. by Cassiano Felippe Gonçalves-de-Albuquerque (846954)

HvPIN1a localisation is influenced by BFA and its expression is decreased by cytokinin. by Gwendolyn K. Kirschner (5142644)

IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)

Models of G48D, M78I, G125C, and A146V RAD52 point mutants. by Abdulaziz B. Hamid (13804692)

Resveratrol decreased tumor latency in <i>Sirt1^Y/+</i> mice. by Katherine V. Clark-Knowles (368164)

Glu58 and Arg87 minimal distance decreases upon activation. by Maxime Louet (150102)

Treatment with wt- or S360A-(A)PC decreases infarct area. by Karin C. A. A. Wildhagen (599651)

<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”

M344 decreases orthotopic pancreatic tumor growth when used as a treatment alone or in combination with gemcitabine. by Shelby M. Knoche (13833807)

Eltrombopag markedly decreases levels of ROS in MOLM14 cells. by Anna Kalota (7415)

“…B) Graphic presentation of ROS levels measured by flow cytometry in cells treated with E (5 μM) or DPI (25 μM), an inhibitor of NADPH oxidase known to decrease an intracellular level of ROS, or untreated (CTR) cells. …”

Compared to vorinostat, M344 decreases pancreatic cancer cell proliferation more effectively for a longer duration. by Shelby M. Knoche (13833807)

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…In the non-recurrence group, CRT improved from 482.5 ± 112.8 to 294.7 ± 65.3, 302.0 ± 68.0, 284.7 ± 55.4, 285.3 ± 70.2, 265.2 ± 65.0, and 266.1 ± 78.2 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g006" target="_blank">Fig 6</a>).…”

Transfer of RSV-infected <i>Kdm5b</i>-deficient DCs leads to a decreased pathogenic pulmonary RSV challenge. by Catherine Ptaschinski (756139)